Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

Regeneron’s Q2 revenue rose 17% year over year to $4.3 billion, while non-GAAP EPS increased 11% to $14.29, supported by Dupixent global sales growth of 38% to $6 billion. Eylea remained a headwind: combined U.S. sales of its original and HD formulations fell 12% to about $1 billion, despite HD sales rising 52% to $596 million. Sanofi expects Dupixent to reach €25 billion ($27.8 billion) in peak revenue by 2030; longer-term growth depends partly on defending the drug against future biosimilars and advancing pipeline candidates, including olatorepatide, which produced up to 19% mean weight loss over 48 weeks in a China Phase 3 study.

Analysis

The key underwriting issue is conversion, not headline drug growth: global Dupixent sales are not equivalent to REGN revenue or profit, given the collaboration split. Track REGN’s collaboration-derived revenue and earnings alongside Sanofi’s global sales; a widening gap would weaken the bull case even if the drug keeps growing. Meanwhile, Eylea HD may slow patient attrition but does not by itself establish that the franchise has found a revenue floor. Continued erosion would pressure the value of REGN’s ophthalmology earnings base and increase the multiple investors assign to a single partnered growth engine. Roche and biosimilar entrants remain relevant competitive pressure points.

Near term, the next earnings update matters more than optimistic peak-sales projections: test Dupixent growth and REGN’s realized economics against ongoing Eylea declines. Over 1–3 months, any clinical or regulatory update could reprice pipeline optionality, but the article supplies no trial timing to underwrite a catalyst trade. Over 6–18 months, the central risk is concentration: pipeline promises do not offset a mature-product decline until trials, regulatory progress, and commercial execution become verifiable. The contrarian point is that headline growth may overstate the durability of REGN’s own earnings, while China Phase 3 weight-loss results are not proof of U.S. efficacy or commercial competitiveness. Without valuation and current consensus data, the evidence supports conditional exposure, not an unconditional re-rating call.

Key Decisions for Investors

• Do not chase REGN solely on global Dupixent sales or projected peak revenue. Before adding, reconcile Sanofi-reported sales with REGN’s collaboration revenue and earnings contribution in the next report.
• Watch Eylea franchise revenue and share trends as a falsification test: persistent combined erosion despite HD adoption would argue that formulation switching is not containing competitive loss.
• Treat olatorepatide as unpriced pipeline optionality, not a near-term earnings offset. Reassess only when U.S. trial design, timing, and data are available; China results alone do not establish a U.S. investment case.
• A starter long in REGN is more defensible after evidence that collaboration-derived earnings remain resilient while Eylea stabilizes; the upside is continued earnings compounding, while the principal downside is simultaneous Eylea erosion and slower-than-expected Dupixent growth. No price-based entry or target is supportable from the supplied information.